Clinical trial software market seen reaching $2.53 billion by 2030
The Business Research Company says the clinical trial software market is expanding as drug research becomes more digitized, data-heavy and decentralized. The firm forecasts the market will grow from $1.51 billion in 2026 to $2.53 billion by 2030, with North America leading and Europe set for the fastest growth.
Why it matters: - Clinical trial software is becoming central to how drug studies are planned, tracked and documented as trials grow more complex. - The market’s growth points to rising demand for tools that improve data accuracy, trial transparency and regulatory compliance. - The forecast suggests more spending on software that can support decentralized trials, remote monitoring and AI-driven workflows.
What happened: - The Business Research Company published its 2026 clinical trial software market report covering market size, trends and a global forecast through 2035. - The report says the market will rise from $1.32 billion in 2025 to $1.51 billion in 2026. - The report projects the market will reach $2.53 billion by 2030. - The firm also offered a free sample of the report. - The full report is available here.
The details: - The report forecasts a 14.1% CAGR from 2025 to 2026. - It forecasts a 13.8% CAGR through 2030. - Growth in the historical period was driven by digitization of clinical trial operations, rising trial data volumes, demand for real-time transparency, global expansion of clinical research and more advanced software platforms. - Future growth is expected to come from virtual and decentralized trials, SaaS-based trial solutions, AI integration, remote patient monitoring and tighter regulatory focus on data integrity. - Key trends expected to shape the market include cloud-based software, AI-driven analytics, decentralized trial platforms, combined electronic data capture and clinical trial management systems, and stronger data security and compliance. - Clinical trial software covers applications used for trial planning, execution and oversight. - The software supports data management, patient recruitment, regulatory adherence and real-time monitoring. - The report says R&D growth is a major driver of demand for clinical trial software. - The report cites UK government net R&D spending of £17.4 billion in 2023, up from £16.1 billion in 2022, according to the Office for National Statistics.
Between the lines: - The forecast reflects a broader shift in drug development toward distributed and data-intensive trial models. - Stronger compliance requirements and rising data volumes are pushing sponsors toward software that can unify workflows instead of patching together multiple tools. - North America’s lead suggests the market is still anchored by established pharma and healthcare infrastructure. - Europe’s projected acceleration points to more adoption of digital trial infrastructure across the region.
What's next: - The market is expected to keep expanding as more sponsors adopt virtual and decentralized trial designs. - More investment should flow into AI, cloud and SaaS platforms that can handle trial data at scale. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - Regional growth beyond North America and Europe will depend on clinical research activity and software adoption in Asia-Pacific, South East Asia, Eastern Europe, South America, the Middle East and Africa.
The bottom line: - Clinical trial software is moving from a back-office tool to a core part of modern drug development, and the market outlook remains strong through 2030.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
United Kingdom Political Times
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.